Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Top advisers to Robert F. Kennedy Jr. are battling over how aggressively to target vaccines during his first days as the ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...